Actinic Keratoses, Keratosis
Conditions
Keywords
Tirbanibulin, Cryotherapy, Squamus cell carcinoma, Skin carcinoma, Actinic Keratosis, Field cancerization
Brief summary
The aim of the study is to evaluate the efficacy and safety of a combined approach of cryotherapy and tirbanibulin for the treatment of actinic keratosis of the scalp and forehead, repeated every 4 months. A higher rate of complete response is expected with this combination compared to cryotherapy alone, as well as a better response with repeated treatment cycles.
Interventions
DRUGCryotherapy + Tirbanibulin
Tirbanibulin ointment applied once daily for 5 days, repeated 3 times (every 4 months)
Sponsors
University Hospital, Lille
Almirall, SAS
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
One single group, each patient serving as their own control, with an intra-individual comparison of one hemiscalp with the contralateral hemiscalp
Intervention model description
One single group, each patient serving as their own control, with an intra-individual comparison of one hemiscalp with the contralateral hemiscalp
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject over 18 years old presenting with ≥ 8 typical actinic keratoses (AK), clinically visible or palpable, grade I or II, with at least 4 AK per hemiscalp, * Participants who, in the investigator's judgment, are in good general condition (ECOG ≤ 2), * The AK must be distributed in 2 non-overlapping areas, and of similar grades, * Patient capable of understanding and adhering to the study visit schedule and other protocol requirements, * Patient capable of understanding and voluntarily signing informed consent, * Patient covered by social insurance, * Patient willing to comply with all study procedures and duration, * Women of childbearing potential must: Have a negative pregnancy test at screening and during the treatment period, Use an effective contraceptive method throughout the study participation. Menopausal women (absence of menstruation for at least one year without other medical cause) or surgically sterile women (tubal ligation, hysterectomy, or bilateral oophorectomy) may be enrolled.
Exclusion criteria
* Clinically atypical and/or rapidly evolving actinic keratoses (AK) in the treatment area, and grade 3 AK according to Olsen classification, * A defined treatment area that would be: 1. Located somewhere other than the scalp and/or forehead, 2. Within 5 cm of a wound that is not fully healed or a lesion suspicious for carcinoma, * Prior treatment with tirbanibulin, * Treatment with 5-fluorouracil (5-FU), imiquimod, ingenol mebutate, diclofenac, photodynamic therapy, or other treatments for actinic keratoses in the treatment area or within 2 cm around this area within 6 weeks prior to the screening visit, * Use of the following therapies within 2 weeks prior to the screening visit: 1. Therapeutic or cosmetic procedures (e.g., liquid nitrogen application, surgical excision, dermabrasion, medium or deep chemical peeling, laser resurfacing) in the treatment area or within 2 cm around the selected treatment area, 2. Therapeutic products containing acids (e.g., salicylic acid, fruit acids), topical retinoids, or light peels in the treatment area or within 2 cm around the selected treatment area, * Allergy to tirbanibulin or any of its components. * Any condition causing a risk of poor compliance, * Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security coverage, refusal to sign the consent form, * Women of childbearing potential who refuse to use an effective contraceptive method, * Pregnant women, women planning to become pregnant, and breastfeeding women, * Persons deprived of liberty by judicial or administrative decision.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete clearance of actinic keratosis | 8 months | Complete clearance rate of actinic keratoses at 8 months. A complete response corresponds to the absence of clinically detectable actinic keratosis in the treated area. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To determine the 12-month effectiveness of a combined approach using cryotherapy and tirbanibulin. | 12 months | Complete Clearance of Actinic Keratosis at 12 months. A complete response corresponds to the absence of clinically detectable actinic keratosis in the treated area. |
| To evaluate the reduction in the number of actinic keratoses after 2 treatment cycles. | 8 months | Partial clearance rate (75% reduction in the number of actinic keratoses) at 8 months. |
| To evaluate the reduction in the number of actinic keratoses after 3 treatment cycles. | 12 months | Partial clearance rate (75% reduction in the number of actinic keratoses) at 12 months. |
| To evaluate the reduction in the need for cryotherapy with tirbanibulin. | 12 months | Number of cryotherapy sessions performed over the entire follow-up period. |
| To describe the safety and tolerability by treated side at each follow-up visit. | 12 months | Safety: Local skin reactions assessed throughout the study |
Outcome results
None listed